CorAlert

Company Overview

Snapshot

Founded in December 2012 by Amir Marmor and Alon Marmor, CorAlert operated with 1–10 employees. The company raised $800,000 across one funding round from two investors. In November 2016, CorAlert secured funding from The Trendlines Group and Israel Innovation Authority.

Business overview

CorAlert developed a noninvasive device designed for the early detection and real-time monitoring of heart failure. Its core technology accurately estimates left ventricular end-diastolic pressure (LVEDP) by analyzing central aortic pressure derived from brachial artery measurements and heartbeat timing. The device provides a comprehensive hemodynamic profile, including the rate of pressure increase in the aorta (dP/dt) and an index correlated to systemic vascular resistance (SVR). CorAlert's solution was validated in clinical trials and served the digital healthcare and medical device sectors, particularly in patient remote monitoring and medical monitors, targeting hospitals and home care markets globally.

Company Intelligence Q&A

What is CorAlert's primary focus?

CorAlert focuses on developing a noninvasive device for the early detection and real-time monitoring of heart failure.

When was CorAlert founded?

CorAlert was founded in December 2012 by Amir Marmor and Alon Marmor.

What was the status of CorAlert as of March 2023?

As of March 2023, CorAlert ceased to operate.

Which organizations participated in CorAlert's funding round?

In November 2016, CorAlert received funding from The Trendlines Group and Israel Innovation Authority.

What is the total disclosed capital raised by CorAlert?

CorAlert raised a total of $800,000 across one funding round.